Purpose: To evaluate the diagnostic performance of PI-RADS v2, proposed adjustments to PI-RADS v2 (PA PI-RADS v2) and biparametric magnetic resonance imaging (MRI) for prostate cancer detection. Methods: A retrospective cohort of 224 patients with suspected prostate cancer was included from January 2016 to November 2018. All the patients underwent a multi-parametric MR scan before biopsy. Two radiologists independently evaluated the MR examinations using PI-RADS v2, PA PI-RADS v2, and a biparametric MRI protocol, respectively. Receiver operating characteristic (ROC) curves for the three different protocols were drawn. Results: In total, 90 out of 224 cases (40.18%) were pathologically diagnosed as prostate cancer. The area under the ROC curves (AUC) for diagnosing prostate cancers by biparametric MRI, PI-RADS v2, and PA PI-RADS v2 were 0.938, 0.935, and 0.934, respectively. For cancers in the peripheral zone (PZ), the diagnostic sensitivity was 97.1% for PI-RADS v2/PA PI-RADS v2 and 96.2% for biparametric MRI. Moreover, the specificity was 84.0% for biparametric MRI and 58.0% for PI-RADS v2/PA PI-RADS v2. For cancers in the transition zone (TZ), the diagnostic sensitivity was 93.4% for PA PI-RADS v2 and 88.2% for biparametric MRI/PI-RADS v2. Furthermore, the specificity was 95.4% for biparametric MRI/PI-RADS v2 and 78.0% for PA PI-RADS v2. Conclusions: The overall diagnostic performance of the three protocols showed minimal differences. For lesions assessed as being category 3 using the biparametric MRI protocol, PI-RADS v2, or PA PI-RADS v2, it was thought prostate cancer detection could be improved. Attention should be paid to false positive results when PI-RADS v2 or PA PI-RADS v2 are used.
The aim of this study was to evaluate the use of Resovist in perfusion-weighted imaging (PWI) of rat hyperacute cerebral infarction. 30 Wistar rats were randomly divided into 2 groups. Group A was intravenously injected with 8 μmol Fe/kg body weight of Resovist, whilst Group B was injected with 0.2 mmol/kg body weight of Gd-DTPA. These dosages were chosen to provide comparable maximum signal changes in normally perfused brain. CBV, CBF and MTT parameter profiles were obtained for the core diseased region and the penumbra of brain ischemia and compared between the two groups. These results were then correlated with pathological findings and TTC staining. In our rat stroke model, signal-time curves were similar between Gd-DTPA and Resovist, both in the core area with severe ischemia and in the penumbra area with moderate ischemia. The CBV, MTT, and TTP values of PWI for ischemic penumbra in Groups A and B showed no statistical disparity. The efficacy of Resovist in MR PWI is similar to Gd-DTPA in the diagnosis of perfusion reduction in the rat stroke model.
1 January 2020 in Brazilian Journal of Pharmaceutical Sciences